News | August 17, 2025
AN2 Therapeutics begins first-in-human trial of oral AN2-502998 for chagas disease
Phase 1 dosing is expected to finish by the end of 2025
Phase 1 dosing is expected to finish by the end of 2025
In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
It is intended for contrast enhancement in MRI scans
Additional data will be presented on a once-weekly oral combination of islatravir and ulonivirine (ISL/ULO) for HIV-1 treatment
The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
SmartTrack aims to reduce the need for clinical studies in generic drug product approvals
Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis
Subscribe To Our Newsletter & Stay Updated
